What we are studying
The type of breast cancer that you have is usually treated after surgery with standard endocrine therapy for at least five years. In this study, standard endocrine therapy will be given to all patients. In addition to standard endocrine therapy, half of the patients (about 400 patients) will receive the study treatment, palbociclib, and the other half will receive a placebo for the same period of time.
If the tests and exams show that you can be in the study and if you agree to take part, you will be randomly assigned (randomized) to one of two Arms (groups): palbociclib or placebo. This means that a computer program will put you into an Arm by chance. Neither you nor your doctor/study team will know which Arm you are in. You will have an equal chance of being placed in either of the two Arms.
You will receive appropriate therapy on either Arm of the study. This means that in all cases you will be treated with endocrine therapy, which is the standard treatment for your stage and type of breast cancer. Your health and well-being will be closely monitored.